<DOC>
	<DOCNO>NCT00847925</DOCNO>
	<brief_summary>A double blind , Placebo ( Vehicle ) Standard Care control , randomise study investigate clinical safety toleration ( include systemic pharmacokinetics ) , wind heal antiscarring potential two application intradermal RN1001 healthy male subject</brief_summary>
	<brief_title>Safety Efficacy RN1001 ( Avotermin ) Healthy Male Subjects</brief_title>
	<detailed_description>Double blind , randomise , Placebo Standard Care control , single centre study . Each subject serve control , i.e . Arm 1 incisions/biopsies randomly receive one two treatment Arm 2 incisions/biopsies receive treatment Arm 1 reverse . The randomisation treatment allow control possible positional effect heal subsequent scarring . Subjects initially dose wound ( incision punch biopsy ) Day 0 re-dosed Day 1 . On Day 3 , Arm 1 incision punch biopsy re-dosed per Day 0 excise , re-dosed Day 4 . Arm 2 punch biopsy excise Day 5 re-dosed . Healed incisions/scars Arm 2 excise histological analysis 12 month re-dosed . All subject , regardless treatment treat accord best practice moist wound healing .</detailed_description>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Healthy , nonAfroCaribbean , male subject age 1845 year inclusive . Weight 60 150kg body mass index 15 55 kg/m2 . Subjects previous history surgery minor injury develop evidence hypertrophic keloid scar formation Subjects direct question physical examination history evidence hypertrophic keloid scarring . AfroCaribbean subject exclude increased susceptibility hypertrophic keloid scarring . Subjects tattoo previous scar area biopsied . Subjects , direct question physical examination , evidence past present clinically significant disease particularly coagulation disorder , immuno mediate condition skin disease allergy , eczema . Subjects history clinically significant allergy , especially drug hypersensitivity lignocaine allergy surgical dressing use study . Subjects clinically significant abnormality follow review pre study laboratory data full physical examination . Subjects take , take , certain prescribed investigational drug three week prior Day 0 particular topical systemic steroid , anticoagulant drug . Certain drug exclude trial . These include OTC analgesic include paracetamol codeine , vitamin mineral supplement , inhale salbutamol , thyroxine replacement therapy , OTC cold remedy . Subjects drink 28 unit alcohol per week ( 1 unit = Â½ pint beer ( 285mls ) 25ml spirit 1 glass wine ) . Subjects current evidence drug abuse . Subjects know serum hepatitis carrier hepatitis B surface antigen hepatitis C antibody . Subjects previous vaccination Hepatitis B exclude per se . Subjects know serum hepatitis carrier hepatitis B core antibody show le 10 unit per litre AntiHBs . Subjects previously positive result test HIV antibody , admit belong highrisk group . In opinion investigator , subject likely complete study ever reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>